Search Results - nb1bxx

4 Results

Sort By:

Glucocerebrosidase Non-inhibitory Chaperones for the Treatment of Gaucher Disease, Parkinson's Disease, and Other Proteinopathies

Gaucher disease is a rare lysosomal storage disease that is characterized by a loss of function of the glucocerebrosidase (GCase) enzyme, which results in a decreased ability to degrade its lipid substrate, glucocerebroside. The intracellular build up of this lipid causes a broad range of clinical manifestations, ranging from enlarged spleen/liver...

Published: 7/25/2024 | Inventor(s): Wei Zheng, Samarjit Patnaik, Noel Southall, Ellen Sidransky, Ehud Goldin, Wendy Westbroek, Steven Rogers, Frank Schoenen, Juan Marugan

Keywords(s): CHAPERONES, Gaucher Disease, GLUCOCEREBROSIDASE, IBXXXX, NB1BXX, NBXXXX, NON-INHIBITORY, Parkinson's Disease, proteinopathy, UAXXXX, VEXXXX, WKXXXX, YAXXXX, YBXXXX

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Neurology, TherapeuticArea > Rare / Neglected Diseases

Therapeutic Approach to Neurodegenerative Disorders Using a TFP5-Peptide

This invention discloses methods for treating neurodegenerative diseases by administering cyclin dependent kinase 5 (Cdk5) inhibitory peptides derived from P35, the activator of Cdk5. Abnormally hyperactive Cdk5 has been shown to be associated with a variety of neurodegenerative disorders. Disclosed in this invention are isolated peptide fragments,...

Published: 7/25/2024 | Inventor(s): Harish (Estate of) Pant

Keywords(s): Approach, DISORDERS, NB1BXX, NB1FXX, NB1XXX, NBXXXX, NEURODEGENERATIVE, NXXXXX, TFP5-peptide, therapeutic

Category(s): Collaboration Sought > Collaboration, Application > Therapeutics, TherapeuticArea > Neurology

Novel Methods for Reducing Inflammation and Treating Diseases such as Parkinson's and Alzheimer's Disease

Microglia activation leads to inflammation mediated dopaminergic degeneration in the brain of patients with Parkinson and Alzheimer's Disease. Thus Identification of drugs that reduce microglia activation could prevent or reverse neuronal degeneration in these diseases and other degenerative CNS disorders. This invention describes small-peptide and...

Published: 7/25/2024 | Inventor(s): Liya Qin, Guorong Li, MIchelle Block, Wei Zhang, Po-See Chen, Giia-Shuen Peng, Jau-Shyong Hong

Keywords(s): Alzheimer disease 1, Alzheimer disease 3, Alzheimer disease 4, Alzheimer disease type 1, Alzheimer disease type 4, Alzheimer disease, familial, type 3, BBXXXX, Discovery, DOSE, femto-molar, IB3XXX, IBXXXX, Inflammation-associated, IXXXXX, Listed LPM Greene as of 4/15/2015, NB1BXX, NBXXXX, NEURODEGENERATIVE, NXXXXX, Parkinson disease 2, Parkinson disease 3, Parkinson disease 9, Parkinson disease, juvenile, autosomal recessive, Parkinson's, Patent Category - Biotechnology, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Prevention, therapeutic, therapeutics, Ultra-low, VEXXXX, WJXXXX, WKXXXX, YAXXXX, YBXXXX, YCXXXX

Category(s): Collaboration Sought > Collaboration, Application > Therapeutics, TherapeuticArea > Neurology, TherapeuticArea > Immunology, Application > Diagnostics, Application > Research Materials

Cell Expansion System For Use In Neural Transplantation

Cell transplantation therapy typically involves transplanting primary cells or immortalized cells into patients. The promising but still inconsistent data stemming from those clinical trials using primary cells in Parkinson's disease are believed to be due to an insufficient number, function and uniformity of the transplanted cells. In an effort to...

Published: 4/8/2024 | Inventor(s): Lorenz Studer, Viviane Tabar, Jun Yan, Ronald McKay

Keywords(s): NB1BXX, NBXXXX, NCXXXX, NXXXXX, Parkinson disease 2, Parkinson disease 3, Parkinson disease 9, Parkinson disease, juvenile, autosomal recessive

Category(s): Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Neurology, Application > Research Materials